Skip to content

Comparation Between Needles for EUS-guided Sampling of Solid Pancreatic Lesions

Prospective Randomized Study Comparing the 25-gauge Franseen Needle and the 25-gauge Standard Needle for EUS-guided Fine-needle Sampling of Solid Pancreatic Lesions Without Rapid on Site Evaluation

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04877340
Enrollment
50
Registered
2021-05-07
Start date
2020-11-26
Completion date
2023-04-30
Last updated
2021-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatic Neoplasms

Keywords

accuracy, pancreatic cancer, endoscopic ultrasound-guided

Brief summary

This is a randomized study in order to compare the diagnostic yield (primary outcome) of EUS-guided sampling of pancreatic solid lesions obtained with the 25-gauge Franseen and the 25-gauge standard needle in patients undergoing EUS-guided sampling of pancreatic solid masses without ROSE. Secondary outcomes are the number of extra passes with each needle required to reach adequate core, possibility to perform immunohistochemistry and the adverse event rate.

Detailed description

This is a randomized trial conducted at a unique center. The aim of this study is to compare the diagnostic yield (primary outcome) of EUS-guided sampling of pancreatic solid lesions obtained with the 25-gauge Franseen and the 25-gauge standard needle in patients undergoing EUS-guided sampling of pancreatic solid masses without ROSE. Secondary outcomes are the number of extra passes with each needle required to reach adequate core, possibility to perform immunohistochemistry and the adverse event rate. Patients with a suspected solid pancreatic lesion larger than 15 mm, identified by CT or MRI and referred to EUS-guided sampling will be eligible for inclusion. Patients will be excluded in case of cystic lesion, or the lesion was not detected in EUS, or if the coagulation parameters are abnormal (INR\> 2, platelet count \< 50,000). The pancreatic mass will be puncture, for expert endoscopist, firstly with a needle according to randomization, followed by another one. Will be make a touch print with the specimen obtained with the needles and, subsequently, all the specimen will be put in formaldehyde solution for cell-block analysis. Diagnostic yield of cell block will be defined as enough histologic tissue core containing pancreatic parenchyma or tumor with dysplastic cells enough for the correct tissue diagnosis. In the presence of malignant tissue in core specimens, it will be calculated the proportion of the area positive for malignancy compared to the total area of the core and then the each needle yield will be defined.

Interventions

DEVICEneedle punction

EUS-guided sampling of pancreatic solid lesions obtained with the 22-gauge

Sponsors

Boston Scientific Corporation
CollaboratorINDUSTRY
Instituto do Cancer do Estado de São Paulo
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

\- solid pancreatic lesion larger than 15 mm

Exclusion criteria

* pancreatic cystic lesion * lesion not detected in EUS * abnormal coagulation parameters (INR\> 2, platelet count \< 50,000)

Design outcomes

Primary

MeasureTime frameDescription
Compare the diagnostic yield2 yearscompare the diagnostic yield between two EUS needles

Secondary

MeasureTime frameDescription
extra passes with each needle2 yearsnumber of extra passes with each needle required to reach adequate core, possibility to perform immunohistochemistry
perform immunohistochemistry2 yearsneed to perform immunohistochemistry to reach the result
adverse event rate2 yearsto assess the adverse event rate

Countries

Brazil

Contacts

Primary ContactFAUZE MALUF-FILHO, PHD
fauze.maluf@terra.om.br+55 (11)38932000
Backup ContactGABRIELA PADUANI, MD
gabrielapaduani@gmail.com+55(11)944605119

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026